Thyromimetics: A review of recent reports and patents (2004 2009)

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 2, 2010, Pages 213-228

  Hirano, Tomoya ^a   Kagechika, Hiroyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Hyperthyroidism; Hypothyroidism; Thyroid hormone; Thyroid hormone receptor; Thyroid hormone receptor agonist; Thyroid hormone receptor antagonist

Indexed keywords

3,5 DIBROMO 3' (2,3 DIHYDRO 3 OXO 6 PYRIDAZINYLMETHYL)THYRONINE; AH 9; AMIODARONE; BENZENE; CGS 23245; CGS 26214; CO 23; GC 1; GC 14; GC 24; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; HY 4; HYDROXYL GROUP; KB 130015; KB 141; KB 2115; KG 8; LIOTHYRONINE; LIOTHYRONINE RECEPTOR; MB 07344; MB 07811; NH 3; THYROID HORMONE RECEPTOR BETA; THYROMIMETIC AGENT; THYROXINE; THYROXINE RECEPTOR; TIRATRICOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; YS 3;

CARDIOVASCULAR SYSTEM; CRYSTAL STRUCTURE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIPID METABOLISM; METABOLIC RATE; NONHUMAN; OXIDATION; OXYGEN CONSUMPTION; PATENT; REVIEW; THYROID GLAND;

DRUG DESIGN; HORMONE REPLACEMENT THERAPY; HUMANS; METABOLIC DISEASES; MOLECULAR MIMICRY; MUTATION; PATENTS AS TOPIC; RECEPTORS, THYROID HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP; THYROID HORMONES;

EID: 76149106851     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903567069     Document Type: Review

References (89)

1. Greenspan FS, Strewler GJ. Basic & clinical endocrinology. 5th edition. Appleton & Lange: Stamford; 1997
2. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1996;83:835-839
3. Lazar MA. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocrinol Rev 1993;14:184-193
4. Johansson C, Vennström B, Thorén P. Evidence that decreased heart rate in thyroid hormone receptor-alpha1-deficient mice is an intrinsic defect. Am J Physiol 1998;275:R640-6
5. Cheng S-Y. Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord 2000;1:9-18
6. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001;81:1097-1142
7. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med 2003;348:2646-2655
8. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-917
9. Gomberg-Maitland M, Frishman WH. Thyroid hormone and cardiovascular disease. Am Heart J 1998;135:187-196
10. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-509
11. Malm J. Therapeutic thyroid hormone ligand patents 1998 - 2003. Expert Opin Ther Pat 2004;14:1169-1183
12. Goslings B, Schwartz HL, Dillmann W, et al. Comparison of the metabolism and distribution of L-triiodothyronine and triiodothyroaeetic acid in the rat: a possible explanation of differential hormonal potency. Endocrinology 1976;98:666-675
13. Beck-Peccoz P, Sartorio A, De Medici C, et al. Dissociated thyromimetic effects of 3,5,3¢-triiodothyroacetic acid (Triac) at the pituitary and peripheral tissue levels. J Endocrinol Invest 1988;11:113-118
14. Messier N, Laflamme L, Hamann G, Langlois MF. In vitro effect of Triac on resistance to thyroid hormone receptor mutants: potential basis for therapy. Mol Cell Endocrinol 2001;174:59-69
15. Underwood AH, Emmett JC, Ellis D, et al. A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature 1986;324:425-429
16. Leeson PD, Ellis D, Emmett JC, et al. Thyroid hormone analogs. Synthesis of 3¢-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart. J Med Chem 1988;31:37-54
17. Yokoyama N, Walker GN, Main AJ, et al. Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine. J Med Chem 1995;38:695-707
18. Ye L, Li Y-L, Mellström K, et al. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor alpha1. J Med Chem 2003;46:1580-1588
19. Chiellini G, Apriletti JW, Yoshihara HA, et al. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 1998;5:299-306
20. Wagner RL, Huber BR, Shiau AK, et al. Hormone selectivity in thyroid hormone receptors. Mol Endocrinol 2001;15:398-410
21. Bleicher L, Aparicio R, Nunes FM, et al. Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms. BMC Struct Biol 2008;8:8
22. Ebisawa M, Inoue N, Fukasawa H, et al. Thiazolidinediones with thyroid hormone receptor agonistic activity. Chem Pharm Bull 1999;47:1348-1350
23. Dow RL, Schneider SR, Paight ES, et al. Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TRalpha subtype-selective thyromimetics. Bioorg Med Chem Lett 2003;13:379-382
24. Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligand-binding domains: three-dimentional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 2000;21:381-388
25. Wagner RL, Apriletti JW, McGrath ME, et al. A structural role for hormone in the thyroid hormone receptor. Nature 1995;378:690-697
26. Baxter JD, Goede P, Apriletti JW, et al. Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology 2002;14:517-524 (Pubitemid 34107205)
27. Chiellini G, Nguyen N-H, Apriletti JW, et al. Synthesis and biological activity of novel thyroid hormone analogues: 5¢-aryl substituted GC-1 derivatives. Bioorg Med Chem 2002;10:333-346
28. Nguyen N-H, Apriletti JW, Cunha Lima ST, et al. Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem 2002;45:3310-3320
29. Nguyen N-H, Apriletti JM, Baxter JD, Scanlan TS. Hammett analysis of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists. J Am Chem Soc 2005;127:4599-4608
30. Shah V, Nguyen P, Nguyen N-H, et al. Complex action of thyroid hormone receptor antagonist NH-3 on gene promoters in different cell lines. Mol Cell Endocrinol 2008;296:69-77
31. Yoshihara HA, Apriletti JW, Baxter JD, Scanlan TS. A designed antagonist of the thyroid hormone receptor. Bioorg Med Chem Lett 2001;11:2821-2825
32. Bakker O, Van Beeren HC, Wiersinga WM. Desethylamiodarone is a noncompetitive inhibitor of the binding of thyroid hormone to the thyroid hormone beta 1-receptor protein. Endocrinology 1994;134:1665-1670
33. Carlsson B, Singh BN, Temciuc M, et al. Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amidarone. J Med Chem 2002;45:623-630
34. Ocasio CA, Scanlan TS. Design and characterization of a thyroid hormone receptor alpha (TRalpha)-specific agonist. ACS Chem Biol 2006;1:585-593
35. Lim W, Nguyen N-H, Yang HY, et al. A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J Biol Chem 2002;277:35664-35670
36. Furlow JD, Yang HY, Hsu M, et al. Induction of larval tissue resorption in Xenopus laevis tadpoles by thyroid hormone receptor agonist GC-1. J Biol Chem 2004;279:26555-26562
37. Cadila Healthcare Limited. Imidazolidinediones and related compounds as selective TR-beta 1 agonist and their preparation, pharmaceutical compositions and use in the treatment of dyslipidemia and obesity. WO2007132475; 2007
38. Hashimoto A, Shi Y, Drake K, Koh JT. Design and synthesis of complementing ligands for mutant thyroid hormone receptor TRalpha(R320H): a tailor-made approach toward the treatment of resistance to thyroid hormone. Bioorg Med Chem 2005;13:3627-3639
39. Haning H, Mueller U, Schmidt G, et al. Novel heterocyclic thyromimetics. Part 2. Bioorg Med Chem Lett 2007;17:3992-3996
40. Komatsu T, Hirano T, Songkram C, et al. Novel thyroid hormone receptor antagonists with an N-alkylated diphenylamine skeleton. Bioorg Med Chem 2007;15:3115-3126
41. Tokyo medical and dental university. Thyroid hormone receptor antagonists containing thiazolidinedione compounds and pharmaceuticals containing them. JP2008189620; 2008
42. Bristol-Myers Squibb Company. Cycloalkyl containing anilide ligands for the thyroid receptor. WO2004066929; 2004
43. Garg N, Li Y-L, Collazo AMG, et al. Thyroid receptor ligands. Part 8: thyromimetics derived from N-acylated-a-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141. Bioorg Med Chem Lett 2007;17:4131-4134
44. Bristol-Myers Squibb Company. Aniline-derived ligands for the thyroid receptor. WO2001060784; 2001
45. Kissei Pharmaceutical Co. Ltd. Malonilic acid derivatives, medicinal compositions containing the same and use thereof. WO2001085670; 2001
46. Bristol-Myers Squibb Company. Substituted anilide ligands for the thyroid receptor. WO2004067482; 2004
47. Berkenstam A, Kristensen J, Mellstrom K, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2008;105:663-667
48. Karo Bio AB. Bristol-Myers Squibb Company. Stable oral pharmaceutical composition containing thyroid hormone receptor agonists. WO2007110226; 2007
49. Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics. WO2005051298; 2005
50. Boyer SH, Jiang H, Jacintho JD, et al. Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J Med Chem 2008;1:7075-7093
51. Erion MD, Cable EE, Ito BR, et al. Targeting thyroid hormone receptor-alpha agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 2007;104:15490-15495
52. Bayer Healthcare AG. Benzofuran derivatives. WO02079181; 2002
53. Karo Bio AB. Idol derivatives as new thyroid receptor agonist ligands and methods. WO2004018421; 2004
54. Collazo AMG, Koehler KF, Garg N, et al. Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor alpha. Bioorg Med Chem Lett 2006;16:1240-1244
55. Borngraeber S, Budny M-J, Chiellini G, et al. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc Natl Acad Sci USA 2003;100:15358-15363
56. Hangeland JJ, Doweyko AM, Dejneka T, et al. Thyroid receptor ligands. Part 2: thyromimetics with improved selectivity for the thyroid hormone receptor beta. Bioorg Med Chem Lett 2004;14:3549-3553
57. Bristol-Myers Squibb Company. Thyroid receptor ligands. WO2004093799; 2004
58. Li Y-L, Litten C, Koehler KF, et al. Thyroid receptor ligands. Part 4: 4¢-amido bioisostetic ligands selective for the thyroid hormone receptor beta. Bioorg Med Chem Lett 2006;16:884-886
59. Koehler K, Gordon S, Brandt P, et al. Thyroid receptor ligands. Part 6: high affinity "direct antagonist" selective for the thyroid hormone receptor. J Med Chem 2006;49:6635-6637 (Pubitemid 44749727)
60. Haning H, Woltering M, Mueller U, et al. Novel heterocyclic thyromimetics. Bioorg Med Chem Lett 2005;15:1835-1840
61. Bayer Healthcare AG. Indoles for treating diseases that can be treated using thyroid hormones. WO0170687; 2001
62. Bayer Healthcare AG. Indazoles having an action similar to that of a thyroid hormone, method for the production thereof, and their use in medicaments. WO0222586; 2002
63. Karo Bio AB. Indole derivatives and their use as thyroid receptor ligands. WO2007134864; 2007
64. Karo Bio AB. Heterocyclic compounds as agonists for the thyroid hormone receptor. WO2007003419; 2007
65. Karo Bio AB. Novel Pharmaceutical Compositions. WO2007128492; 2007
66. F. Hoffmann-La Roche AG. Pyridazinone derivatives as thyroid hormone receptor agonists. WO2007009913; 2007
67. F. Hoffmann-La Roche AG. Prodrugs to thyroid hormone analogues. WO2009037172; 2009
68. Koh JT. Engineering control over protein function; transcriptional control by small molecules. Chapter 3.3. In: Schreiber SL, Kapoor T, Wess G, editors, Chemical biology. (Volume 1). Wiely-VCH Verlag GmbH & Co. KGaA: Weinheim; 2007
69. Ye H, O'Reilly KE, Koh JT. A subtype-selective thyromimetic designed to bind a mutant thyroid hormone receptor implicated in resistance to thyroid hormone. J Am Chem Soc 2001;123:1521-1522
70. Shi Y, Ye H, Link KH, et al. Mutant-selective thyromimetics for the chemical rescue of thyroid hormone receptor mutants associated with resistance to thyroid hormone. Biochemistry 2005;44:4612-4626
71. Nomura Y, Nagaya T, Tsukaguchi H, et al. Amino acid substitutions of thyroid hormone receptor-beta at codon 435 with resistance to thyroid hormone selectively alter homodimer formation. Endocrinology 1996;137:4082-4086
72. Ando S, Sarlis NJ, Oldfield EH, Yen PM. Somatic mutation of TRalpha can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab 2001;86:5572-5576
73. Hassan AQ, Koh JT. A functionally orthogonal ligand-receptor pair created by targeting the allosteric mechanism of the thyroid hormone receptor. J Am Chem Soc 2006;128:8868-8874
74. Hassan AQ, Koh JT. Selective chemical rescue of a thyroid-hormone- receptor mutant, TRalpha(R435Y), identified in pituitary carcinoma and resistance to thyroid hormone. Angew Chem Int Ed 2008;47:7280-7283
75. Shibusawa N, Hashimoto K, Nikrodhanond AA, et al. Thyroid hormone action in the absence of thyroid hormone receptor DNA-binding in vivo. J Clin Invest 2003;112:588-597
76. Hiroi Y, Kim- H-H, Ying H, et al. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 2006;103:14104-14109
77. Scanlan TS, Suchland KL, Hart ME, et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 2004;10:638-642
78. The reagents of the university of California; Oregon health & science university. Thyronamine derivatives and analogs and methods of used thereof. WO2004093800; 2004
79. Hedfors A , Appelqvist T, Carlsson B, Bladh L-G, Litten C, Agback P, Grynfarb M, Koehler KF, Malm J. Thyroid receptor ligands. Part 3: design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem 2005;48:3114-3117
80. Karo Bio AB. Preparation of 4-benzyloxyphenylalkanoic acids and analogs as thyroid receptor antagonists for the treatment of cardiac and metabolic disorders. WO2001036365; 2001
81. Karo Bio AB. Thyroid hormone receptor antagonists for cardiac and metabolic disorders II. WO2002092550; 2002
82. Shiau AK, Barstad D, Radek JT, et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 2002;9:359-364
83. Malm J, Gordon S, Brandt P, et al. Thyroid receptor ligands. Part 7: indirect antagonists of the thyroid hormone receptor with improved affinity. Bioorg Med Chem Lett 2007;17:2018-2021
84. Karo Bio AB. Thyroid receptor agonists. WO2005092317; 2005
85. Karo Bio AB. Novel pharmaceutical compositions comprising agonists of the thyroid hormone receptor. WO2005092316; 2005
86. Hangeland JJ, Friends TJ, Doweyko AM, et al. A new class of high affinity thyromimetics containing a phenyl-naphthylene core. Bioorg Med Chem Lett 2005;15:4579-4584
87. Bristol-Myers Squibb Company. Phenyl naphthol ligands for thyroid hormone receptor. US2003166724; 2003
88. New York University. Driverse thyroid hormone receptor antagonists and uses thereof. WO2004103289; 2004
89. Cadila Healthcare Limited. Selective TR-beta 1 agonist. WO2008062469; 2008